ID30262A - Ligan reseptor melanokortin - Google Patents

Ligan reseptor melanokortin

Info

Publication number
ID30262A
ID30262A IDW00200102111A ID20012111A ID30262A ID 30262 A ID30262 A ID 30262A ID W00200102111 A IDW00200102111 A ID W00200102111A ID 20012111 A ID20012111 A ID 20012111A ID 30262 A ID30262 A ID 30262A
Authority
ID
Indonesia
Prior art keywords
melanokortin
ligan
receptor
ligan receptor
Prior art date
Application number
IDW00200102111A
Other languages
English (en)
Indonesian (id)
Inventor
Adam W Mazur
Feng Wang
Russell J Sheldon
Frank H Ebetino
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of ID30262A publication Critical patent/ID30262A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
IDW00200102111A 1999-03-29 2000-03-21 Ligan reseptor melanokortin ID30262A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12667399P 1999-03-29 1999-03-29

Publications (1)

Publication Number Publication Date
ID30262A true ID30262A (id) 2001-11-15

Family

ID=22426131

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200102111A ID30262A (id) 1999-03-29 2000-03-21 Ligan reseptor melanokortin

Country Status (34)

Country Link
US (2) US6613874B1 (fr)
EP (1) EP1165613B1 (fr)
JP (1) JP2002542159A (fr)
KR (2) KR100519201B1 (fr)
CN (1) CN1249086C (fr)
AR (1) AR023201A1 (fr)
AT (1) ATE393783T1 (fr)
AU (1) AU763510B2 (fr)
BR (1) BR0009497A (fr)
CA (1) CA2368431C (fr)
CO (1) CO5170531A1 (fr)
CZ (1) CZ20013407A3 (fr)
DE (1) DE60038734T2 (fr)
DK (1) DK1165613T3 (fr)
ES (1) ES2304345T3 (fr)
HK (1) HK1044954B (fr)
HU (1) HUP0202203A3 (fr)
ID (1) ID30262A (fr)
IL (1) IL145406A0 (fr)
MA (1) MA25403A1 (fr)
MX (1) MXPA01009881A (fr)
MY (1) MY126585A (fr)
NO (1) NO20014568L (fr)
NZ (1) NZ514141A (fr)
PE (1) PE20001641A1 (fr)
PL (1) PL350095A1 (fr)
PT (1) PT1165613E (fr)
RU (1) RU2213098C2 (fr)
SA (1) SA00210192B1 (fr)
SK (1) SK13082001A3 (fr)
TR (1) TR200102765T2 (fr)
TW (1) TWI250990B (fr)
WO (1) WO2000058361A1 (fr)
ZA (1) ZA200107411B (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
CA2377369A1 (fr) 1999-06-04 2000-12-14 Merck & Co., Inc. Piperidines substituees en tant qu'agonistes du recepteur de melanocortine-4
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6693165B2 (en) 2000-01-18 2004-02-17 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
PL366630A1 (en) 2000-08-30 2005-02-07 F.Hoffmann-La Roche Ag Selective cyclic peptides
NZ524190A (en) * 2000-09-27 2004-09-24 Procter & Gamble Melanocortin receptor ligands
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
CA2453515A1 (fr) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Peptides lineaires et cycliques specifiques du recepteur de melanocortine
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
AU2004251616A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(MC4) agonists and their uses
JP2006527772A (ja) * 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン３受容体（ｍｃ３ｒ）作用薬ペプチドの用途
MXPA06003474A (es) * 2003-09-30 2006-06-05 Novo Nordisk As Agonistas de receptores de melanocortina.
WO2005044839A2 (fr) * 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Peptides stabilises structures en helice alpha et leurs utilisations
AU2015201062B2 (en) * 2003-11-05 2017-03-09 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
JP2007530674A (ja) * 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用
EP1804798A4 (fr) * 2004-10-05 2008-01-23 Merck & Co Inc Procedes de traitement d'un abus d'une substance d'une addiction a cette substance
WO2006060873A1 (fr) * 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Procede de restauration de la fonction reproductrice
WO2006073771A2 (fr) * 2005-01-05 2006-07-13 Eli Lilly And Company Peptides d'agonistes mc4r ou mc3r lies au polyethyleneglycol
WO2006073772A1 (fr) * 2005-01-05 2006-07-13 Eli Lilly And Company Peptides agonistes de mc4r ou de mc3r lies a un polyethyleneglycol
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US7754691B1 (en) 2005-07-07 2010-07-13 Palatin Technologies, Inc. Linear melanocortin receptor-specific peptides for cachexia
KR100997177B1 (ko) * 2005-07-08 2010-11-29 입센 파마 에스.에이.에스 멜라노코르틴 수용체 리간드
AU2006269321A1 (en) * 2005-07-08 2007-01-18 Ipsen Pharma S.A.S. Ligands of melanocortin receptors
WO2007077112A1 (fr) * 2005-12-30 2007-07-12 F. Hoffmann-La Roche Ag Procede de synthese de peptides contenant arginine
EP2348016B1 (fr) 2006-06-09 2016-02-17 SynAct Pharma ApS Dérivés de phényl pyrrole aminoguanidin
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
BRPI0720306A2 (pt) * 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
CA2678941C (fr) * 2007-02-23 2018-11-27 Aileron Therapeutics, Inc. Systemes macrocycliques de triazole
JP5631201B2 (ja) * 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
EP2148692B1 (fr) 2007-05-25 2017-01-25 Ipsen Pharma S.A.S. Ligands de récepteurs de la mélanocortine modifiés au moyen d'hydantoïne
CN104474529A (zh) 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
WO2009126292A2 (fr) * 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques biologiquement actifs
TW201002340A (en) * 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
WO2009152079A1 (fr) 2008-06-09 2009-12-17 Palatin Technologies, Inc. Peptides spécifiques du récepteur de mélanocortine pour le traitement d'un dysfonctionnement sexuel
US20110144306A1 (en) * 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
CN104961795A (zh) 2008-09-22 2015-10-07 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
AU2010204648B2 (en) 2009-01-14 2016-09-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2440572B1 (fr) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Peptides spécifiques des récepteurs aux mélanocortines à pont lactame
EA020959B1 (ru) 2009-06-08 2015-03-31 Палатин Текнолоджиз, Инк. Пептиды, специфичные к меланокортиновым рецепторам
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
BR112012000867A2 (pt) 2009-07-13 2019-09-24 Harvard College "polipeptídeos bifuncional costurado e uso do mesmo"
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
JP2013510881A (ja) * 2009-11-16 2013-03-28 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Ａｃ−Ａｒｇ−シクロ（Ｃｙｓ−Ｄ−Ａｌａ−Ｈｉｓ−Ｄ−Ｐｈｅ−Ａｒｇ−Ｔｒｐ−Ｃｙｓ）−ＮＨ２の合成のための方法
EA021897B1 (ru) 2009-11-23 2015-09-30 Палатин Текнолоджиз, Инк. Циклические пептиды, специфичные к рецептору меланокортина-1
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
CN101824415A (zh) * 2010-03-31 2010-09-08 华东师范大学 黑素皮质1型受体基因的snp及其应用
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012040459A2 (fr) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Peptides de ciblage de la béta-caténine et leurs utilisations
WO2012100342A1 (fr) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine et dérivés de pyrazolopyrimidine en tant que modulateurs du récepteur de la mélanocortine-4
WO2012174423A1 (fr) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Polypeptides stabilisés comme régulateurs de fonction gtpase rab
EP2768518A4 (fr) 2011-10-18 2015-05-27 Aileron Therapeutics Inc Macrocycles peptidomimétiques
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
CA2864120A1 (fr) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Macrocycles peptidomimetiques reticules par triazole et par thioether
RS61957B1 (sr) 2012-09-26 2021-07-30 Harvard College Uvezani peptidi blokirani prolinom i njihove upotrebe
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
KR20150131244A (ko) 2013-03-13 2015-11-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스테이플드 및 스티치드 폴리펩티드 및 그의 용도
BR112015031277A2 (pt) 2013-06-14 2017-09-19 Harvard College Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos
EP3145523A4 (fr) 2014-05-21 2018-02-21 President and Fellows of Harvard College Peptides inhibiteurs de ras et leurs utilisations
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
EP3197478A4 (fr) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leurs utilisations
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3347372A4 (fr) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques en tant que modulateurs de mcl-1
PT3773558T (pt) 2019-05-10 2022-09-13 Synact Pharma Aps Tratamento combinado de doença artrítica
CN110681362B (zh) * 2019-09-26 2020-09-11 浙江大学 以羧基和吲哚基为功能基团的混合模式层析介质
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
US11932628B2 (en) 2021-01-04 2024-03-19 Regents Of The University Of Minnesota Selective small molecule peptidomimetic melanocortin ligands
AU2022296767A1 (en) 2021-06-21 2024-02-01 Synact Pharma Aps Phenyl pyrrole aminoguanidine salts and formulations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462927A (en) 1985-04-30 1995-10-31 The Administrators Of The Tulane Educational Fund Peptides aiding nerve regeneration
ATE109793T1 (de) 1987-05-22 1994-08-15 University Patents Inc Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
WO1989002897A1 (fr) 1987-09-24 1989-04-06 The Administrators Of The Tulane Educational Fund Peptides a usage therapeutique
ZA908610B (en) 1989-11-03 1991-08-28 Univ Tulane Peptides aiding nerve regeneration
ES2089256T3 (es) 1991-02-15 1996-10-01 Takeda Chemical Industries Ltd Antagonista de la endotelina.
ATE155486T1 (de) 1991-08-13 1997-08-15 Takeda Chemical Industries Ltd Zyklische peptide und ihre verwendung
RU2096415C1 (ru) * 1991-09-30 1997-11-20 Дзе Дюпон Мерк Фармасьютикал Компани Циклические пептиды или их фармацевтически приемлемые соли, фармацевтическая композиция
EP0552417B1 (fr) 1991-11-19 1999-07-07 Takeda Chemical Industries, Ltd. Peptides cycliques et leurs utilisations
EP0547317A1 (fr) 1991-12-19 1993-06-23 Takeda Chemical Industries, Ltd. Antagonistes d'endothéline
DE9203901U1 (de) 1992-03-24 1992-07-16 Croon & Lucke Maschinenfabrik Gmbh, 7947 Mengen Gestell zum Lagern von flächigen Werkstücken
DE69330868T2 (de) 1992-07-27 2002-04-25 Biomeasure, Inc. Antagonisten des neuromedin b rezeptors
US5569741A (en) 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
AU673731B2 (en) 1993-06-03 1996-11-21 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonistic peptide
EP0714909A1 (fr) 1994-12-01 1996-06-05 Takeda Chemical Industries, Ltd. Composition pour la prévention et le traitement de maladies de la circulation pulmonaire
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
AU5514396A (en) 1995-04-28 1996-11-18 Takeda Chemical Industries Ltd. Cyclic pentapeptide lh-rh receptor antagonists
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
DE69719320T2 (de) 1996-06-11 2003-12-11 Novartis Ag, Basel Kombination eines somatostatin analogs und eines rapamycins
WO1997049724A1 (fr) 1996-06-25 1997-12-31 Nisshin Flour Milling Co., Ltd. Depsipeptides cycliques et medicaments contenant ces composes comme ingredient actif
US6251861B1 (en) 1996-06-27 2001-06-26 Takeda Chemical Industries, Ltd. Treatment of cerebral infarction using cyclic hexapeptides
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
WO1998027113A2 (fr) 1996-12-17 1998-06-25 Quadrant Holdings Cambridge Limited Melanocortines
SE9700620D0 (sv) * 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight

Also Published As

Publication number Publication date
DK1165613T3 (da) 2008-08-25
JP2002542159A (ja) 2002-12-10
KR100519201B1 (ko) 2005-10-06
PL350095A1 (en) 2002-11-04
ES2304345T3 (es) 2008-10-16
EP1165613A1 (fr) 2002-01-02
TR200102765T2 (tr) 2002-05-21
AU763510B2 (en) 2003-07-24
NZ514141A (en) 2004-01-30
WO2000058361A1 (fr) 2000-10-05
TWI250990B (en) 2006-03-11
US6951916B2 (en) 2005-10-04
KR100558131B1 (ko) 2006-03-10
CN1249086C (zh) 2006-04-05
CO5170531A1 (es) 2002-06-27
HK1044954A1 (en) 2002-11-08
AU4017900A (en) 2000-10-16
SK13082001A3 (sk) 2002-03-05
HUP0202203A2 (en) 2002-10-28
CN1345335A (zh) 2002-04-17
DE60038734T2 (de) 2009-07-02
ZA200107411B (en) 2002-05-29
CA2368431A1 (fr) 2000-10-05
US20040023859A1 (en) 2004-02-05
MXPA01009881A (es) 2002-05-06
NO20014568L (no) 2001-11-29
MY126585A (en) 2006-10-31
CA2368431C (fr) 2006-01-24
CZ20013407A3 (cs) 2002-02-13
HK1044954B (en) 2008-11-21
KR20050009722A (ko) 2005-01-25
US6613874B1 (en) 2003-09-02
KR20020008143A (ko) 2002-01-29
SA00210192B1 (ar) 2006-06-04
BR0009497A (pt) 2002-01-15
AR023201A1 (es) 2002-09-04
EP1165613B1 (fr) 2008-04-30
IL145406A0 (en) 2002-06-30
DE60038734D1 (de) 2008-06-12
PT1165613E (pt) 2008-07-29
ATE393783T1 (de) 2008-05-15
NO20014568D0 (no) 2001-09-20
HUP0202203A3 (en) 2003-09-29
PE20001641A1 (es) 2001-02-07
RU2213098C2 (ru) 2003-09-27
MA25403A1 (fr) 2002-04-01

Similar Documents

Publication Publication Date Title
DE60020617D1 (de) Zementierkopf
DE69932238D1 (de) Epoxidierungsverfahren
NO20016115L (no) Substituerte heterosykelkondenserte gamma-karbolin
PT1224180E (pt) Azois substituidos
PT1210113E (pt) Composicoes de vacinas de combinacao
DE69915610D1 (de) Epoxidierungsverfahren
PT1218009E (pt) Grandulos de quetiapina
NO20013997L (no) Reseptoranalyse
PT1218096E (pt) Microcapsulas de libertacao variavel
PT1163256E (pt) Hemi-hidrato de 16-alfa-bromoepiandrosterona
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
PT1235566E (pt) Formulacao injectavel de valnemulina
DE60028852D1 (de) Fixiervorrichtung
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
DE60026931D1 (de) Ausrichtung von Ausdrucken
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
NO20022927L (no) Substituerte pyrrazoler
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
DE50006201D1 (de) Bohle
DK1194426T3 (da) Benzofuranderivater
PT1175417E (pt) Compostos substituidos de benzolactamas
ID30381A (id) Penggunaan arilalkanoilpiridazina
DE50005694D1 (de) Zentrifuge
PT1232141E (pt) Eteres de o-desmetil-venlafaxina
DK1030319T3 (da) Ringkerne